Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics

BMY POWR Grades

• Value is the dimension where BMY ranks best; there it ranks ahead of 98.02% of US stocks.
• BMY's strongest trending metric is Growth; it's been moving down over the last 177 days.
• BMY's current lowest rank is in the Momentum metric (where it is better than 3.78% of US stocks).

BMY Stock Summary

• BRISTOL MYERS SQUIBB CO's market capitalization of $123,048,162,047 is ahead of 98.45% of US-listed equities.
• BRISTOL MYERS SQUIBB CO's stock had its IPO on January 1, 1986, making it an older stock than 93.16% of US equities in our set.
• Of note is the ratio of BRISTOL MYERS SQUIBB CO's sales and general administrative expense to its total operating expenses; just 13.32% of US stocks have a lower such ratio.
• Stocks that are quantitatively similar to BMY, based on their financial statements, market capitalization, and price volatility, are GILD, ADI, AMGN, DE, and PFE.
• Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Valuation Summary

• BMY's price/sales ratio is 2.7; this is 42.11% higher than that of the median Healthcare stock.
• BMY's price/sales ratio has moved up 0.1 over the prior 243 months.

Below are key valuation metrics over time for BMY.

BMY Growth Metrics

The 4 year cash and equivalents growth rate now stands at 304.53%.
• Its 3 year net cashflow from operations growth rate is now at 163.12%.
• The 2 year net cashflow from operations growth rate now stands at 53.2%.

BMY's revenue has moved up $2.6194e+10 over the prior 70 months.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-12-31	46,159	13,066	6,327
2022-09-30	46,738	13,817	6,677
2022-06-30	47,144	15,396	6,617
2022-03-31	46,960	16,195	6,251
2021-12-31	46,385	16,207	6,994
2021-09-30	45,468	15,820	-5,405

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BMY has a Quality Grade of B, ranking ahead of 79.64% of graded US stocks.
• BMY's asset turnover comes in at 0.38 -- ranking 124th of 680 Pharmaceutical Products stocks.
• PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.